News Hub | News Direct

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

drive21, Van Wagner Collaborate to Elevate In-Venue Branding and Fan Engagement Across College Athletics

drive21

drive21, a leader in experiential design and marketing solutions, today announced a strategic relationship with leading collegiate athletics marketing agency, Van Wagner to become a preferred experiential graphic design and implementation provider for Van Wagner. Van Wagner is recognized for its expertise in collegiate sponsorship sales and multi-media rights and will collaborate with drive21 to redefine branding strategies, drive revenue growth, and create Name, Image and Likeness (NIL) execution opportunities in the collegiate sports industry. Through this relationship, Van Wagner’s collegiate clients will be afforded advantageous pricing and access to drive21’s suite of services to provide innovative branding and design solutions across their venues; driving innovative solutions that bridge the gap between brand aspirations and reality, creating immersive environments that resonate with audiences and drive tangible business results. "This relationship represents a significant step forward in our mission to transform sports and entertainment venues into impactful environments that are also powerful marketing tools," said Warren Godridge, drive21 Founder and President. "By collaborating with Van Wagner, we can leverage our creativity and expertise to deliver a consistent brand experience across all venues, enhancing the value for brands, universities, and fans alike." “Traditional approaches often focus solely on aesthetics and overlook the potential to maximize partnership, sponsorship and NIL opportunities, leaving untapped value on the table” said John Libro, Head of Sports and Entertainment at drive21. “Working with Van Wagner College will allow us to push the boundaries of experiential design and transform collegiate athletic facilities into dynamic revenue-generating tools that engage fans and drive real business growth.” This relationship may also offer an even more comprehensive solution to collegiate clients by providing new NIL revenue streams. Through this collaboration with drive21, a portion of the facility’s expenditure can be reallocated to the universities’ NIL efforts. This allows universities to offer a more engaging experience for athletes and fans while creating dynamic environments supporting athletic performance, fan engagement and brand partnerships. "drive21’s ability to seamlessly integrate brand experiences into our facilities is a game-changer for our clients,” said Mark Donley, Chief Revenue Officer at Van Wagner College. “Through our arrangement with drive21, our university clients have an opportunity to access the expertise of drive21 to not only enhance their facilities but also ensure a consistent and high-quality experience for a variety of initiatives at an advantageous rate. It's truly a win-win-win scenario." The first major joint effort was a collaboration at Florida International University for the brand implementation of the newly named Pitbull Stadium. drive21 and Van Wagner played a key role in creating cohesive branding for the first college athletic venue named after a musician, exampling the transformative potential of experiential design and strategic branding. To learn more about the partnership, or drive21’s sports, entertainment and hospitality solutions, please visit www.drive21.com. About drive21 drive21 elevates the sports, entertainment, and hospitality industries by delivering one-of-a-kind branded venue experiences. A leader in experiential design and marketing solutions, drive21 bridges the gap between imagination and reality to deliver functional and impactful environments through design, fabrication, implementation, and holistic project management. Servicing organizations including MLB, MLS and NCAA institutions, drive21 helps its clients maximize partnership and sponsorship revenue and turns ordinary environments into extraordinary works of art. For more information, visit www.drive21.com. About Van Wagner Van Wagner is a leading sports advertising and entertainment agency with global expertise in filmed and live entertainment, sponsorship sales, multi-media rights, and aerial advertising. Van Wagner creates, advises, and sells for world-class teams, leagues, brands, and properties. An innovator in the sports and media business, Van Wagner is a global leader in high-impact broadcast visible signage throughout the MLB, NBA, NCAA, and international soccer, sponsorships sales, college multi-media rights, and in-venue content production at the world’s biggest sporting events. For more information, visit www.vanwagner.com. Contact Details Hot Paper Lantern Jackson Gaskins jgaskins@hotpaperlantern.com Company Website https://drive21.com

September 25, 2024 08:00 AM Eastern Daylight Time

AI Unpacks Generational Stereotypes, Highlighting Key Differences, but Beer Bridges the Gap

AIport

What happens when you ask generative AI models to depict Baby Boomers, Gen X, Millennials, and Gen Z? You might expect tech-challenged Boomers and avocado-loving Millennials. But what you get is far more interesting and in some cases, unexpected. A joint research project conducted by AIport and Turing Post last month analyzed over 1200 AI-generated images across four different models—Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG. The findings have revealed both familiar stereotypes and surprising quirks about how AI perceives these generations. Sad Boomers, Happy Zoomers? Contrary to the carefree Boomer stereotype, AI models like Midjourney depict Baby Boomers as introspective, or even somber, often bundled up and gazing wistfully into the distance—a reflection, perhaps, of their disillusionment with the unfulfilled ideals of the 1960s cultural revolution. However, the ERNIE-ViLG model, likely trained on datasets with a more collectivist cultural slant, shows 93% of Boomers smiling. This fascinating contrast underscores the cultural differences embedded in different AI models. Meanwhile, Gen Z’s images are vibrant and diverse, reflecting their reputation as a generation that embraces individuality, inclusivity, and self-expression. The AI-generated images depict Zoomers in colorful, highly detailed scenarios, making them the most visually distinct generation in the study. Generations Through the AI Lens The research explored how generations are portrayed in five key aspects of life: identity, relationships, work, lifestyle, and consumer habits. The AI models revealed consistent patterns and stereotypes; for example, males predominated in the depictions of Boomers and Gen Xers across all four models, while many images of Millennials and Zoomers showed greater diversity and more female representation. Surprisingly, Gen X appears to be the least well-understood generation by AI, characterized by fewer defining features compared to all other generations, likely due to the limited amount of training data available. The one stereotypical Gen X leitmotif that AI consistently identifies is their fondness for flannel shirts—an unmistakable symbol of the 1990s grunge scene worn by Gen Xers who were rebellious teenagers and young adults during that era. As for one (un)expected commonality… It’s beer. Whether they’re Millennials job-hopping or Boomers reminiscing about the good old days, AI consistently showed beer in 34% of the produced images across all generations. Prompt Engineering and AI Insights The prompts for this research were carefully crafted to avoid bias, using neutral phrases like "A Millennial at work" or "A Boomer relaxing." The results offer a telling look at how generative AI models mirror societal stereotypes, often shaped by the data they're trained on. These findings open the door to deeper discussions on how AI reflects, and sometimes distorts, cultural narratives. "Whether we think we can learn about generations from these images depends upon how confident we feel that the training data that went in is an accurate image of the self identity of a group,” explains Senior Engineer and Sociologist Stephanie Kirmer, who analyzed the findings. “For the younger sets, I don’t think we can know how much of it is media representation created by people outside the group versus how much is selfie-style personal expression. Some of what we’re getting, especially for the older groups who don’t contribute as much self-generated visual media online, is perceptions of that group from advertising and media, which we know has inherent flaws." About the Study The study examined the outputs of four globally recognized generative AI models, each with distinct aesthetic and cultural nuances, providing a comprehensive look at how each generation is portrayed visually. The selected models included Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG, offering diverse perspectives from different regions across the globe. Conclusion Whether confirming or contradicting societal stereotypes, AI-generated images provide a fascinating snapshot of how technology interprets generational differences. The fact that beer remains a unifying theme across all four models shows that, no matter our age, some things—like enjoying a cold one—transcend generational divides. To learn more about the project, visit https://www.aigenerations.tech/. Hero images for the media: Google Drive Link About AIport AIport is an emerging community of AI/ML enthusiasts and practitioners with a goal of providing a truly global view of the AI/ML/DS landscape. https://www.blog.aiport.tech/ About Turing Post Turing Post is everything you need to make smarter decisions about AI. https://www.turingpost.com/ Contact Details Nick Leighton nick.leighton@nettresultsllc.com Company Website https://www.aigenerations.tech/

September 23, 2024 10:00 AM Eastern Daylight Time

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

VOESH New York Launches New 28 oz. Vegan Hand & Body Crème Collection

VOESH New York

VOESH New York is debuting a new 28 oz. Vegan Hand & Body Crème Collection, created to provide salon clients with a luxurious and healthier hydration experience. These larger bottles offer the same high-quality, vegan-friendly ingredients that have established VOESH as a leader in the body care industry. “We’re thrilled about the addition of these generously sized lotions to VOESH’s product line,” said Tom Harrison, Principal of Coleman Harrison. “VOESH consistently outshines the competition with expert formulas. This new size will undoubtedly enhance manicure and pedicure services, delivering superior results for both clients and technicians.” “As a bonus, technicians can pair these lotions with VOESH’s best-selling Pedi in a Box products,” added Kendall Stone, Principal of Jay Stone Sales. Enriched with 94+% natural-origin ingredients, VOESH’s 28 oz. crèmes are formulated with organic virgin olive oil and natural extracts. They are infused with 100% vegan, clean, and certified organic components and are free from parabens, phthalates, gluten, mineral oil, and more than 1,680 other potentially harmful substances. The velvety texture provides long-lasting moisture and a radiant glow without a greasy feel. These larger bottles not only provide a superior experience but also ensure lasting hydration and value. “Our lotions have always been a best-seller, so we’ve brought them back in a more convenient size for salons,” said Joseph Choi, Co-Founder of VOESH New York. “Salon owners have been asking for our popular massage butter in a bottle, and we’re ecstatic to fulfill this request.” The new collection is available in five delightful scents: Olive Sensation, Lavender Relieve, Vitamin Recharge, Jasmine Soothe, and Green Tea Detox. Each scent is made with premium, IFRA-certified fragrances that pair perfectly with VOESH’s best-selling Pedi in a Box Deluxe 4 Step pedicure kits. This allows for a cohesive pampering experience that caters to clients’ preferences. With a transparent ingredient list, dermatologist testing, and U.S. FDA registration, VOESH’s new 28 oz. Vegan Hand & Body Crèmes are the best addition to guarantee clients and technicians feel good about what goes on their skin. For more information about VOESH’s new 28 oz. Vegan Hand & Body Crèmes, please visit voeshpro.com. About VOESH New York: Founded in 2013, VOESH New York has emerged as a premier destination for clean and efficacious body care solutions catering to head-to-toe wellness. Noteworthy products include Pedi in a Box, Mani in a Box, the award-winning Shower & Empower Vitamin C Shower Filter, and Collagen Gloves and Socks. VOESH New York is committed to providing 100% vegan, cruelty-free, and sustainable products because every body deserves better beauty! All VOESH New York products are certified by PETA and registered with the US Mocra, EU CPNP and UK SCPN, maintaining vegan, cruelty-free, and dermatologist-tested standards. VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. For more information, visit VOESH New York’s website at Voesh.com or contact press@voesh.com. All VOESH New York products are certified by PETA and registered with the EU CPNP, and UK SCPN. Always vegan, cruelty-free, and dermatologist-tested, VOESH New York proudly excludes all 1,680+ EU-banned ingredients and an additional 400+ potentially harmful ingredients. Contact Details Colleen Mathis +1 917-690-5560 Colleen@absoluterrelations.com Company Website https://voesh.com/

September 06, 2024 08:00 AM Eastern Daylight Time

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

PRSA Colorado Chapter Announces Winners of the 2024 Gold Picks Awards

PRSA Colorado

The Colorado Chapter of the Public Relations Society of America (PRSA Colorado) hosted its highly anticipated 2024 Gold Picks Awards Ceremony last night at Stick and Feather in Denver, Colo. The event, which has become a cornerstone of the Colorado public relations community, celebrated the outstanding achievements of professionals and organizations in the field of public relations and corporate communications. Honoring Two Pioneers A highlight of the evening was the presentation of Special Awards, including the Jane Dvorak Mentor of the Year Award and the Sharon Linhart PR Person of the Year Award. These awards were renamed at the event in honor of two trailblazers in the Colorado PR community, recognizing their extraordinary contributions to the industry. The 2024 Special Awards winners are: Joe Fuentes Rookie of the Year: Caroline Campbell, VISIT DENVER Jane Dvorak Mentor of the Year Award: Shawna Seldon McGregor, Maverick Public Relations Media Person of the Year: Greg Avery, Denver Business Journal Business Person of the Year: Doyle Albee, Comprise PR Team of the Year: Gomez Howard Group Ayers Chapter Service Award: Liz Viscardi, APR, LV Events and PR Sharon Linhart PR Person of the Year Award: Merideth Hartung, B Public Relations Rising Stars and Industry Leaders The event also shone a spotlight on the next generation of PR professionals. Members of the Public Relations Student Society of America (PRSSA) from the University of Colorado Boulder and Colorado State University were acknowledged for their contributions to the event and their dedication to the profession. The PRSSA's efforts in fundraising and their anticipated participation in the ICON conference in Anaheim, Calif. this fall were particularly commended. 2024 Gold Picks Award Winners All award winners are listed below under their corresponding category. Gold Picks are the highest-scoring awards based on a specific scoring system but each award is judged individually instead of against the other submittals within that category, meaning multiple organizations can win a Gold Pick within the same category. All awards are judged anonymously by another chapter of PRSA. Gold and Silver Pick Awards: Integrated Communications: Consumer Products: Gold: SchroderHaus – "Justin’s Nuts About Bees" Silver: SchroderHaus – "Justin’s #JustinMyLunch Hunger Relief Program" Government: Gold: CIG Public Relations – "Express Lanes Safety Enforcement" Silver: CIG Public Relations – "CDOT’s Cannabis-Impaired Driving Campaign" Associations/Nonprofits/Educational Institutions: Silver: SchroderHaus – "Fairtrade America’s 'We Are Fairtrade.' Awareness Campaign" Events and Observances - Seven or Fewer Days: Government: Gold: National Disabled Veterans Winter Sports Clinic – "Miracles on a Mountainside" Silver: National Renewable Energy Laboratory – "NREL Welcomes Neighbors Back to Campus During Community Open House" Associations/Nonprofits/Educational Institutions: Gold: Meadows PR and Visit Golden – "Goldens in Golden" Silver: CU Boulder Office of Strategic Relations & Communications – "ScienceWriters2023 at CU Boulder" Silver: Metropolitan State University of Denver – "9News Denver Mayoral Debate hosted by MSU Denver" Content Marketing: Government: Silver: CIG Public Relations – "CDOT Motorcycle Safety campaign" Business to Business: Silver: Graebel Companies with Linhart Public Relations – "Amplifying Thought Leadership and Demonstrating Value through Creative Storytelling" Silver: BOK Financial – "Healthcare Cyberattacks Hurt Providers and Patients Alike" Community Relations: Associations/Nonprofits/Educational Institutions: Silver: JKD & Company and The Church of Jesus Christ of Latter-day Saints – "11th Hour Push - Denver’s Giving Machines" Climate Action and Environmental Sustainability: Silver: SideCar Public Relations – "Seizing Streets for Community Not Cars: ¡Viva! Streets Denver Brings a Global Phenomenon to the Mile High City" Influencer Marketing: Micro-Influencers: Silver: SchroderHaus – "Increasing Reach and Credibility through Influencer Partnerships for Clipper Tea" Organizational Awards: Best Agency - Midsize: Gold: B Public Relations – "From Local to Global: B Public Relations Elevates Hospitality Brands and Experiences" Component Awards: Annual Reports: Gold: Western Resource Advocates – "WRA’s 2022 Impact Report - Building a Better West" Gold: JKD & Company – "Native American Bank - Honoring Community" Social Media: Gold: CU Boulder Office of Strategic Relations & Communications – "CU in 60" Gold: SchroderHaus – "Leveraging Social Media for Awareness and Engagement for Clipper Tea" Branded Content: Gold: BOK Financial – "Healthcare Cyberattacks White Paper" Feature Stories: Gold: Linhart Public Relations with Spire Midstream – "Contributed Content Highlights Need for Natural Gas Storage" Gold: CU Boulder Office of Strategic Relations & Communications – "How Animals Get their Stripes and Spots" Gold: Metropolitan State University of Denver – "Call Me Mister" Newsletters/Magazines: Gold: Metropolitan State University of Denver – "RED Newsfeed" Gold: Western Resource Advocates – "Field Notes" Best Use of Generative AI - Direct Audience Engagement: Gold: CIG Public Relations – "CDOT Impaired Driving Holiday Mug Shot Campaign" Data Insights: Gold: Hensel Phelps Marketing Communications Team & Swing Strategic Communication – "Hensel Phelps 2023 Communications Audit" Influencer Marketing: Gold: Linhart Public Relations with Chocolove – "Sweet Success: Activating Existing Brand Fans on Instagram by Showing the Chocolove" Gold: SchroderHaus – "Justin’s #JustinMyLunch Influencer Marketing" Gold: SchroderHaus – "Earth Month Goes Regenerative for Artisan Tropic" Videos: Silver: Metropolitan State University of Denver – "Art of Dueling" Websites: Gold: Western Resource Advocates – "A New Website for Western Resource Advocates’ Future" Podcasts: Silver: National Renewable Energy Laboratory – "NREL Reaches New Audiences with Launch of Science News Podcast" Media Relations: Gold: JKD & Company and The Church of Jesus Christ of Latter-day Saints – "11th Hour Push - Denver’s Giving Machines" Gold: Linhart Public Relations – "Beef. It’s What’s For Dinner. Combines Bench of Culinary Experts and Creative Media Strategy to Garner Year-Round National Media Coverage" Silver: CU Boulder Office of Strategic Relations & Communications – "Full Triceratops Skeleton Now Calls Boulder Home" Silver: SideCar Public Relations – "¡Viva! Streets Denver Drives Sustainability and Community Engagement Through Car-Free Streets" Silver: Barefoot PR – "Delta Dental of Colorado Foundation Invests in Oral Health Equity" Silver: Elasticity on behalf of Elevate Quantum – "A Mountain of Opportunity" Silver: Root Marketing & PR on behalf of Bubbies Fine Foods – "Making a Big Dill Out of Bubbies" Grand Gold Picks: The Grand Bold Pick is awarded to the "Best of Show" for the campaign with the highest overall score. This years, two organizations took home a Grand Gold Pick: Meadows PR and Visit Golden – "Goldens in Golden" National Disabled Veterans Winter Sports Clinic – "Miracles on a Mountainside" PRSA Colorado congratulates all winners for their exemplary work and contributions to the public relations industry in Colorado. The Public Relations Society of America ( www.prsa.org ) is the nation’s largest association for the professional practice of public relations. The Colorado Chapter ( www.prsacolorado.org ), headquartered in Westminster, is consistently one of the largest chapters in the country. The chapter provides timely and profession-specific educational programs, information and networking opportunities to all of its members, which include professionals at all levels working at corporations, local and national public relations agencies, government offices, universities, nonprofits and independent PR practitioners. Contact Details PRSA Colorado Chapter Alicia Nieva-Woodgate +1 415-515-0866 info@prsacolorado.org Company Website https://prsacolorado.org/

August 29, 2024 04:24 PM Eastern Daylight Time

Nuvectis Pharma Rises in Pre-Market Following FDA Orphan Drug Designation for NXP800, Fueling Optimism Ahead of Key Clinical Data

Global Markets News

Nuvectis Pharma (NASDAQ: NVCT) has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation for its lead candidate, NXP800. This designation, specifically for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers, marks a critical step forward in Nuvectis’s mission to address unmet needs in oncology. Orphan Drug Designation: A Strategic Advantage The FDA’s Orphan Drug Designation is awarded to drugs that show promise in treating rare diseases affecting fewer than 200,000 people in the U.S. For Nuvectis, this designation not only validates the potential of NXP800 but also provides several strategic benefits. These include tax credits for clinical trial costs, exemption from certain FDA fees, and potentially seven years of market exclusivity upon approval. NXP800 targets ARID1a-deficient cancers, a subset of ovarian cancers that present significant treatment challenges. The Orphan Drug Designation underscores the importance of this candidate in potentially offering a new, more effective treatment option for patients with this specific genetic mutation. Background and Market Impact This latest achievement builds on Nuvectis Pharma’s earlier successes. Earlier this year, the FDA granted Fast Track Designation to NXP800 for its development in platinum-resistant, ARID1a-mutated ovarian cancer. The Fast Track status, combined with the Orphan Drug Designation, highlights the urgent need for innovative treatments in this space and positions NXP800 as a potential game-changer in oncology. Financial analysts have taken note of Nuvectis’s progress. H.C. Wainwright recently reiterated its buy rating for Nuvectis, setting a price target of $21. This optimistic outlook reflects the market’s confidence in the company’s strategic direction, particularly as it prepares to release key clinical data later this year. Anticipation for Upcoming Results The next few months are expected to be pivotal for Nuvectis Pharma. The company is poised to share updates from its ongoing Phase 1b clinical trial of NXP800, which targets patients with platinum-resistant, ARID1a-mutated ovarian cancer. This trial is being closely watched, as positive results could significantly advance the development of NXP800, bringing it closer to pivotal trials and eventual regulatory approval. Additionally, Nuvectis is also conducting a Phase 1a dose escalation study for NXP900, its second key candidate, which targets YES1/SRC-driven tumors. Updates from this study are expected to provide further insights into the safety and potential efficacy of NXP900. ### Nuvvectis' Full announcment, titled " Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers" was published on August 29th, 2024. ### This article is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. https://justpaste.it/fcm9n/pdf. Global Markets News Network is a commercial digital brand compensated to provide coverage of innovative companies and industries and it is thus subject to conflicts of interest. Contact Details Global Markets News News Coverage ronald@futuremarketsresearch.com

August 29, 2024 08:20 AM Eastern Daylight Time

How Seniors Can Benefit from Flip Phones

Spark Metro

In a world increasingly dominated by smartphones and constant connectivity, the simplicity of flip phones remains a compelling choice, particularly for seniors. While modern smartphones offer a multitude of features, their complexity can often be overwhelming for those who prioritize ease of use and straightforward functionality. For seniors, the balance between staying connected and maintaining simplicity is crucial, making flip phones an ideal solution. This article explores the many advantages of flip phones for seniors, highlighting how these devices offer a perfect blend of traditional simplicity and modern technology. The Appeal of Simplicity One of the most significant advantages of flip phones for seniors is their simplicity. Unlike smartphones, which require navigating complex menus and apps, flip phones offer a more straightforward interface. The act of flipping open the phone to answer a call and closing it to hang up is intuitive and familiar, providing a sense of nostalgia and comfort to many users. This simplicity reduces the learning curve, allowing seniors to use their phones confidently without needing extensive technical knowledge. Moreover, the tactile buttons on flip phones are often larger and more spaced out than those on smartphones, making them easier to press. This is particularly important for seniors who may struggle with dexterity or have vision impairments. The physical feedback of pressing a button, as opposed to the touchscreens of smartphones, adds to the ease of use, ensuring that seniors can make calls and send texts with minimal frustration. Enhanced Security and Privacy Another key advantage of flip phones for seniors is the enhanced security and privacy they offer. Smartphones are often vulnerable to various security threats, from phishing scams to malware, due to their internet connectivity and app usage. In contrast, flip phones have limited internet capabilities, significantly reducing the risk of cyber threats. For seniors who may not be as tech-savvy or aware of online risks, this limitation becomes a protective feature. Furthermore, flip phones typically do not store as much personal information as smartphones, which decreases the potential impact of losing the device. Seniors can feel more secure knowing that their personal data is less likely to be compromised if their phone is misplaced or stolen. This peace of mind is invaluable for those who prioritize security and privacy. Superior Battery Life Battery life is another area where flip phones excel, making them particularly well-suited for seniors. Smartphones are notorious for their relatively short battery life, often requiring daily charging due to their power-hungry apps and features. On the other hand, flip phones are designed with efficiency in mind, and their limited features contribute to significantly longer battery life. For seniors, the ability to go several days without needing to charge their phone is a major advantage. It reduces the hassle of constantly monitoring battery levels and ensures that their phone is always ready for use, particularly in emergencies. This reliability is a crucial factor for seniors who may not want to worry about their phone dying at an inconvenient time. Durability and Robust Design Flip phones are also known for their durability, a feature that is particularly important for seniors. The robust design of flip phones makes them less susceptible to damage from drops and other accidents, which are common concerns for users of all ages. The clamshell design not only protects the screen when the phone is closed but also adds a layer of protection against everyday wear and tear. This durability means that seniors can use their flip phones for extended periods without the need for frequent repairs or replacements. The sturdy construction of flip phones also makes them easier to handle, reducing the likelihood of accidental drops. For seniors, the combination of durability and ease of use ensures that their phone remains a reliable companion in their daily lives. Choosing the Right Flip Phone When selecting a flip phone for a senior, it's essential to consider specific features that cater to their needs. User-friendly features, reliable service, and a robust design are all critical factors to ensure that the phone meets their requirements. For instance, the Consumer Cellular IRIS Flip is an excellent option for seniors, offering a range of features designed with ease of use in mind. The large, easy-to-read display, intuitive navigation, and enhanced sound quality make it particularly suitable for those with vision or hearing impairments. Additionally, the IRIS Flip includes emergency response features, providing an added layer of security for seniors who may need assistance quickly. Its durable design ensures that it can withstand daily use, while the extended battery life means that seniors can rely on their phone to be ready when they need it most. The Importance of Reliable Service In addition to selecting a phone with the right features, it's also crucial to choose a provider that offers reliable service. For seniors, having a dependable network is essential for staying connected with family, friends, and emergency services. When considering a flip phone, ensure that the provider offers strong coverage in your area and has a reputation for excellent customer service. A good provider will also offer flexible plans that cater to the needs of seniors, such as low-cost options for those who primarily use their phone for calls and texts. This flexibility ensures that seniors are not paying for features they do not need, making their phone plan more affordable and tailored to their usage patterns. The Modern Benefits of a Traditional Design While flip phones may seem like a relic of the past, they continue to offer significant advantages in the digital age, especially for seniors. Their simplicity, enhanced security, superior battery life, and durability make them an attractive option for those who value straightforward, reliable communication. In addition to these benefits, modern flip phones have incorporated certain technological advancements that enhance their functionality without compromising their user-friendly design. Features such as voice commands, text-to-speech, and enhanced sound quality have been integrated into many flip phones, providing seniors with the convenience of modern technology while maintaining the simplicity they prefer. Conclusion For seniors, the choice of a mobile phone should prioritize ease of use, reliability, and security. Flip phones, with their intuitive design and practical features, offer a compelling solution that meets these needs. While smartphones dominate the market with their endless apps and features, the straightforward nature of flip phones provides a refreshing alternative, ensuring that seniors can stay connected without the complexity and distractions of more advanced devices. The Consumer Cellular IRIS Flip exemplifies the best of both worlds, combining the simplicity of a flip phone with carefully selected modern features that enhance usability and safety. By choosing the right flip phone, seniors can enjoy the benefits of staying connected while maintaining control over their digital experience. Contact Details Alex +1 302-597-6768 Apexreviews154@gmail.com

August 27, 2024 03:52 AM Eastern Daylight Time

Image